The global human immunoglobulin (pH4) for intravenous injection market is a multibillion-dollar industry. Human immunoglobulin (pH4) for intravenous injection is derived from pooled human plasma. It is administered intravenously to provide immediate, though temporary, increases in patient IgG antibody levels to treat various primary immunodeficiency diseases.
The global human immunoglobulin (pH4) for intravenous injection Market is estimated to be valued at US$ 9.7 billion in 2023 and is expected to exhibit a CAGR of 16% over the forecast period 2023-2031, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The rising prevalence of primary immunodeficiency diseases is fueling the growth of the human immunoglobulin (pH4) for intravenous injection market. According to the latest statistics provided by the World Health Organization, the prevalence rate of primary immunodeficiency is 1:1000-1:10000 people worldwide. Moreover, studies reveal that the frequency is likely to increase with better diagnostics. As human immunoglobulin (pH4) for intravenous injection is the standard treatment for patients with most primary immunodeficiency diseases, the rising prevalence of these diseases is directly contributing to market growth.
SWOT Analysis
Strength: This market provides immunoglobulins with low pH levels in order to reduce the risk of adverse reactions. The IgG molecules have good thermal stability and purity that provides effective treatment.
Weakness: The production and purification process requires sophisticated technologies and expertise which increases the cost of production. Clinical trials need to continuously evaluate the safety, efficacy and adherence to quality standards.
Opportunity: Rising cases of immunodeficiency and neurological disorders are driving the demand. New production technologies and expansion to emerging markets will aid future growth.
Threats: Stringent regulations for plasma collection, production and quality can increase compliance costs. Supply issues and entry of biosimilars are challenges to established brands.
Key Takeaways
The global Human Immunoglobulin (pH4) for Intravenous Injection market is expected to witness high growth over the forecast period. The North American region currently dominates the market due to rising healthcare expenditure, expanding patient pool and presence of major manufacturers.
Regional analysis: North America is the highest revenue generating region currently due to growing healthcare investments, established biopharmaceutical industry capabilities and presence of major market players. The widespread acceptance of immunoglobulin therapy for various conditions also supports market growth.
Key players: Key players operating in the Human Immunoglobulin (pH4) for Intravenous Injection market are CSL Behring, Grifols, Octapharma, Kedrion Biopharma, China Biologic Products. These players are focusing on capacity expansions, new product development and market consolidation activities to strengthen their global presence.
*Note:
- Source: Coherent Market Insights, Public sources, Desk research
- We have leveraged AI tools to mine information and compile it
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. With an MBA in E-commerce, she has an expertise in SEO-optimized content that resonates with industry professionals.